Essex Property Trust Stock Trails Market What Analysts See for This West Coast REIT EU Plans to Impose Significant Fine on Google Handelsblatt Reports Nvidia Earnings Call in Spotlight Geopolitical Crossroads as Trump China Chips Loom Financial Services Market Roundup Experian SoFi Technologies in Focus Social Security Timing Dilemma Claim Now or Wait for Survivor Benefits at 67 Paul Tudor Jones No Chance Kevin Warsh Can Push the Fed to Cut Rates XENE Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Advances UroGen Pharma Ltd URGN Q1 2026 Earnings NarrowerthanExpected Loss Drives Positive Stock Reaction VICR Q1 2026 Earnings EPS Surprises 1983 Above Estimates as Stock Declines Slightly Werewolf Therapeutics HOWL Q1 2026 Earnings NarrowerthanExpected Loss Highlights Operational Discipline TRINZ Q1 2026 Earnings Slight EPS Beat Amid Stable Operations DDS Q1 2026 Earnings Earnings Miss Estimates but Stock Rises 18 Corporacion America Airports CAAP Holds Near Resistance as Volume Signals Caution Western Asset Bond Fund WEA Edges Higher as FixedIncome Investors Assess Rate Outlook OraSure Technologies OSUR Surges 9 Key Levels to Watch After Strong Move Goldman Sachs STRATS Trust GJS Holds Steady at 2345 as Price Action Remains Rangebound Ooma Inc OOMA Drops Nearly 9 as Shares Approach Key Support Zone Novartis Upgrades FullYear Outlook on Strong Operational Performance AIHS Q1 2026 Earnings Reported Net Loss Persists Amidst Operational Challenges Tyson Foods TSN Faces Selling Pressure Testing Key Support Levels AZZ Q1 2026 Earnings EPS Beat Delivers Solid Start to Fiscal Year ORGN Q4 2025 Earnings Steep Loss Misses Wide Estimates as Stock Rallies One Stop Systems OSS Q1 2026 Earnings Surprise Profit Beats Expectations Stock Rises 523 Adagene Q2 2025 Earnings Clinical Progress Overshadows EPS Miss Shares Jump Trump Postpones AI Executive Order Signing Citing Concerns Over Potential Blocking Effects SpaceX IPO Speculation Nvidia Earnings and Bezos on AI Bubble Key Market Insights BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development